This could be experimentally validated by screening series of prostate cancer cells (LAPC4, LNCaP) to determine whether ACBD6 is present, and in those cell lines in which it is present, siRNA knockdown of ACBD6 could be performed do to functional assays, such as proliferation in hormone sensitive (LNCaP) and hormone resistant cell lines (LNCaP-abl). Here, ACBD6 is linked to prostate cancer.